Literature DB >> 8165595

Thapsigargin amplifies the platelet procoagulant response caused by thrombin.

E F Smeets1, J W Heemskerk, P Comfurius, E M Bevers, R F Zwaal.   

Abstract

The platelet procoagulant response involves an increase in surface-exposed phosphatidylserine, which allows binding and assembly of enzyme complexes of the coagulation pathway resulting in acceleration of the clotting process. This response essentially requires the presence of extracellular Ca2+, and varies in extent with the type of agonist used. In the present paper we demonstrate that the moderate procoagulant response of human platelets caused by thrombin is strongly amplified by the presence of thapsigargin, an inhibitor of the microsomal Ca(2+)-ATPase. Thapsigargin, like thrombin, has only a weak effect on procoagulant activity. The large increase in procoagulant activity observed with the combined action of these two agonists is associated with increased shedding of microvesicles from the platelet plasma membrane as well as with inhibition of transport of a fluorescent-labeled analog of phosphatidylserine from the outer to the inner leaflet of the plasma membrane by the aminophospholipid translocase. The latter two observations support current concepts regarding the mechanism of development of procoagulant activity. Although the synergistic effect of thapsigargin on thrombin-induced procoagulant activity is at least in part due to the high levels of intracellular [Ca2+] evoked by these agonists, the data clearly indicate that a rise of the intracellular [Ca2+] is insufficient to completely explain this response. The present findings suggest that additional factors control expression of procoagulant activity upon stimulation of platelets by thrombin.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8165595

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  8 in total

1.  PAR-1-stimulated factor IXa binding to a small platelet subpopulation requires a pronounced and sustained increase of cytoplasmic calcium.

Authors:  Fredda S London; Mariola Marcinkiewicz; Peter N Walsh
Journal:  Biochemistry       Date:  2006-06-13       Impact factor: 3.162

2.  Agonist-induced platelet procoagulant activity requires shear and a Rac1-dependent signaling mechanism.

Authors:  Michael Keegan Delaney; Junling Liu; Kyungho Kim; Bo Shen; Aleksandra Stojanovic-Terpo; Yi Zheng; Jaehyung Cho; Xiaoping Du
Journal:  Blood       Date:  2014-07-25       Impact factor: 22.113

3.  Quantitative determination of the binding of beta2-glycoprotein I and prothrombin to phosphatidylserine-exposing blood platelets.

Authors:  Edouard M Bevers; Marie P Janssen; Paul Comfurius; Krishnakumar Balasubramanian; Alan J Schroit; Robert F A Zwaal; George M Willems
Journal:  Biochem J       Date:  2005-03-01       Impact factor: 3.857

4.  Monitoring Endoplasmic Reticulum Calcium Homeostasis Using a Gaussia Luciferase SERCaMP.

Authors:  Mark J Henderson; Emily S Wires; Kathleen A Trychta; Xiaokang Yan; Brandon K Harvey
Journal:  J Vis Exp       Date:  2015-09-06       Impact factor: 1.355

5.  Protein kinase Ctheta negatively regulates store-independent Ca2+ entry and phosphatidylserine exposure downstream of glycoprotein VI in platelets.

Authors:  Matthew T Harper; Alastair W Poole
Journal:  J Biol Chem       Date:  2010-04-13       Impact factor: 5.157

6.  Mitochondrial calcium and reactive oxygen species regulate agonist-initiated platelet phosphatidylserine exposure.

Authors:  Hyo-Jung Choo; Talib B Saafir; Laura Mkumba; Mary B Wagner; Shawn M Jobe
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-10-18       Impact factor: 8.311

7.  Real-time analysis of platelet aggregation and procoagulant activity during thrombus formation in vivo.

Authors:  Tadataka Hayashi; Hideo Mogami; Yusuke Murakami; Toshio Nakamura; Naohiro Kanayama; Hiroyuki Konno; Tetsumei Urano
Journal:  Pflugers Arch       Date:  2008-06-14       Impact factor: 3.657

8.  Impaired mitochondrial activity explains platelet dysfunction in thrombocytopenic cancer patients undergoing chemotherapy.

Authors:  Constance C F M J Baaten; Floor C J I Moenen; Yvonne M C Henskens; Frauke Swieringa; Rick J H Wetzels; René van Oerle; Harry F G Heijnen; Hugo Ten Cate; Graham P Holloway; Erik A M Beckers; Johan W M Heemskerk; Paola E J van der Meijden
Journal:  Haematologica       Date:  2018-06-07       Impact factor: 9.941

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.